All News

Article

Big Time Vasculitis (3.10.2023)

Jack Cush, MD Mar 10, 2023

Dr. Jack Cush Reviews the News and Journal articles from the past week on RheumNow. This weeks highlights includes insights on scleroderma, myositis, vasculitis and answers the question - does aggressive biologic treatment of psoriasis prevent future psoriatic arthritis?

Article

Renal Involvement is Pivotal in ANCA-Associated Vasculitis

MedPage Today Mar 06, 2023

Bearing in mind that renal impairment is among the worst complications of ANCA-associated vasculitis (AAV), researchers have identified four different trajectories of kidney function over time in AAV patients, with implications for personalized treatment, as well as future research.

Article

NSAIDs in Pregnancy (3.3.2023)

Jack Cush, MD Mar 03, 2023

Dr. Jack Cush reviews the lastest journal articles, news, and FDA announcements from the past week on RheumNow. This week, the importance of IFNa, Subclinical PsA and NSAID safety during Pregnancy.

Article

Treat-to-Target Guidelines for GCA and PMR

Jack Cush, MD Feb 28, 2023

The Annals of Rheumatic Disease has published updated multinational, treat-to-target (T2T) recommendations for the treatment of giant cell arteritis (GCA) and polymyalgia rheumatica (PMR).

Article

Burnout #10 (2.3.2023)

Jack Cush, MD Feb 03, 2023

Dr. Jack Cush reviews the past week of news on RheumNow.com.

Article

PsA Til Death Do Us Part (1.20.2023)

Jack Cush, MD Jan 20, 2023

Dr. Jack Cush reviews the highlights from the past week on RheumNow.com.

GCA patients with AORTITIS proven by CTA or FDG-PET/CT have higher rates of relapse. Among 82 GCA pts, 78% positive on both CTA & PET. Relapse was seen in 70% in the CTA+/PET+ group & 29% in the CTA-/PET+ (p = 0.019). https://t.co/2zU9ueWkEZ https://t.co/aFn2xH6KmI

https://bit.ly/3YDMOlU

https://bit.ly/3Lbped9

BRIDGE-PMR a proof-of-concept trial studied 1 dose of IV RTX in 47 PMR pts - at 1 yr, 52% RTX were in GC-free remission (compared to 21% given PBO). Eight (33%) patients in the placebo group and six (26%) in the rituximab group had adverse events https://t.co/yv8ezFN5BJ https://t.co/7FOOPbEIf3

https://bit.ly/3JmDHkQ

Renal Involvement is Pivotal in ANCA-Associated Vasculitis Researchers have identified four different trajectories of kidney function over time in AAV patients, with implications for personalized treatment, as well as future research. https://t.co/O8EaW2MaBx https://t.co/VApYiH66yn

https://bit.ly/3ZuTDHr

ENT involvement studied in 320 ANCA associated vasculitis pts: 65% had ENT involvement w/ median age =52 yrs, & median BVAS3 = 12. Relapse seen in 29% despite immunosupp Rx. No diff in outcomes betw pts Rx w/ oral or IV CTX or RTX https://t.co/MwZSnVVd32 https://t.co/YbrHxnqDw9

https://bit.ly/3YtLTUP

Study of 197 AAV pts in RAVE trial (RTX vs CTX; followed by AZA) showed most serious infections (82%) occurred in 6 mos (68% Resp infx) & assoc w/ lower#s CD19+ cells. TMP/SMX prophylaxis against P. jirovecii decreased SIE rates https://t.co/oz530OkGs8 https://t.co/YFW7PD6wrW

https://bit.ly/41R6W6W

Study of 78 pt suspected of #GCA undergoing Temp. artery Bx and US. Nearly half (35) Dx w/ GCA. Both had similar sensitivities(69% and 63%, respectively), but specificity higher w/ biopsy (100% vs 79%). Compression sign had best diagnostic performance https://t.co/wzVqrHvfqM https://t.co/HRmfb6g7aF

https://bit.ly/3EXR0Wm

https://bit.ly/3Y9D3LN

Vision Loss with ANCA-Associated Vasculitis Shelley K. Dhillon, MD, presents her poster at RWCS 2023. https://t.co/e25SFDXk7O https://t.co/J1AsdE3b0Y

https://bit.ly/41hppcj

PR3 autoreactive CD4+T cells found in affected kidneys of 72 pts with PR3+ ANCA assoc vasculitis. These cytotoxic GPR56+CD4+T cells were significantly greater in those with inactive (vs active GPA), suggesting they may be affected by immunosuppression https://t.co/dHFhgnB8yE https://t.co/ZxV6INeCrU

https://bit.ly/3xCjjFP

Lg vessel US study compared 44 LV-GCA vs 42high-risk atherosclerosis pt.Intima-media thickness (IMT) was signif. higher w/ GCA. IMT ≥ 1 mmseen in 31/44 axillary, 30/44 subclavian in GCA; but only in 2/42 axillary & 3//42 subclavian in atherosclerosis grp.https://t.co/DGMOfflcVR https://t.co/QVBbdrcd3I

https://bit.ly/3k0mTXe

197 ANCA assoc Vasculitis pts in RAVE - treated w/ RTX or CTX, thenAZA. 18/22 severe infections occurred within 6 months. Predictors of severe infx included higher baseline CD19+B cells & PJP prophylaxis w/ TMP/SMX (both groups Rx RTX or CYC/AZA) https://t.co/YhNDCdJuof https://t.co/Fg8AOLtYbI

https://bit.ly/3Y7a37L

US study of 47 #GCA pts showed baseline US+ in 44/47 (72% TA, 72% LV). US was sensitivity to change over time w/ serial measures. TA-based US showed good correlation w/ Dz activity & discriminated remission vs, relapse https://t.co/2cDxac5oJw https://t.co/jH4rgvgELY

https://bit.ly/3GVRHjr

International survey of 394 GPs & 937 rheumatologists shows most PMR pts are not referred to Rheum. GPs referred 25% suspected PMR for Dx & 50% were returned to GP. 39% of Rheums saw new PMR >2 weeks after referral, half already on Pred https://t.co/K56nYRckpz https://t.co/j6ukqPaQXd

https://bit.ly/3Wjva5K

Topics

All News

Big Time Vasculitis (3.10.2023)

Renal Involvement is Pivotal in ANCA-Associated Vasculitis

NSAIDs in Pregnancy (3.3.2023)

Treat-to-Target Guidelines for GCA and PMR

Burnout #10 (2.3.2023)

PsA Til Death Do Us Part (1.20.2023)

Do you get our email newsletter?